CA2533377A1 - Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds - Google Patents

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds Download PDF

Info

Publication number
CA2533377A1
CA2533377A1 CA002533377A CA2533377A CA2533377A1 CA 2533377 A1 CA2533377 A1 CA 2533377A1 CA 002533377 A CA002533377 A CA 002533377A CA 2533377 A CA2533377 A CA 2533377A CA 2533377 A1 CA2533377 A1 CA 2533377A1
Authority
CA
Canada
Prior art keywords
chr
group
same
different
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002533377A
Other languages
French (fr)
Other versions
CA2533377C (en
Inventor
Singh Rajinder
Argade Ankush
Hui Li
Somasekhar Bhamidipati
David Carroll
Catherine Sylvain
Jeffrey Clough
Holger Keim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals, Inc.
Singh Rajinder
Argade Ankush
Hui Li
Somasekhar Bhamidipati
David Carroll
Catherine Sylvain
Jeffrey Clough
Holger Keim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc., Singh Rajinder, Argade Ankush, Hui Li, Somasekhar Bhamidipati, David Carroll, Catherine Sylvain, Jeffrey Clough, Holger Keim filed Critical Rigel Pharmaceuticals, Inc.
Publication of CA2533377A1 publication Critical patent/CA2533377A1/en
Application granted granted Critical
Publication of CA2533377C publication Critical patent/CA2533377C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Abstract

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

Claims (50)

1. A 2,4 pyrimidinediamine compound according to structure:
including salts, hydrates, solvates and N-oxides thereof, wherein:
L1 is a direct bond or a linker;
L2 is a direct bond or a linker;
R4 is X is selected from the group consisting of N and CH;
Y is selected from the group consisting of O, S, SO, SO2, SONR36, NH, NR35 and NR37;
Z is selected from the group consisting of O, S, SO, SO2, SONR36, NH, NR35 and NR37;
R5 is selected from the group consisting of R6, (C1-C6) alkyl optionally substituted with one or more of the same or different R8 groups, (C1-C4) alkanyl optionally substituted with one or more of the same or different R8 groups, (C2-C4) alkenyl optionally substituted with one or more of the same or different R8 groups and (C2-C4) alkynyl optionally substituted with one or more of the same or different R8 groups;
each R6 independently is selected from the group consisting of hydrogen, an electronegative group, -OR d, -SR d, (C1-C3) haloalkyloxy, (C1-C3) perhaloalkyloxy, -NR c R c, halogen, (C1-C3) haloalkyl, (C1-C3) perhaloalkyl, -CF3, -CH2CF3, -CF2CF3, -CN, -NC, -OCN, -SCN; -NO, -NO2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR c R c; -S(O)2NR
c R c, -OS(O)R d, -OS(O)2 R d, -OS(O)2OR d, -OS(O)NR c R c, -OS(O)2NR c R c, -C(O)R d, -C(O)OR
d, -C(O)NR c R c, -C(NH)NR c R c, -OC(O)R d, -SC(O)R d, -OC(O)OR d, -SC(O)OR d, -OC(O)NR c R c, -SC(O)NR c R c, -OC(NH)NR c R c, -SC(NH)NR c R c, -[NHC(O)]n R d, -[NHC(O)]n OR d, -[NHC(O)]n NR c R c and -[NHC(NH)]n NR c R c, (C5-C10) aryl optionally substituted with one or more of the same or different R8 groups, phenyl optionally substituted with one or more of the same or different R8 groups, (C6-C16) arylalkyl optionally substituted with one or more of the same or different R8 groups, 5-10 membered heteroaryl optionally substituted with one or more of the same or different R8 groups and 6-16 membered heteroarylalkyl optionally substituted with one or more of the same or different R8 groups;
R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b, -(CHR a)m-R b, -O-(CH2)m-R b, -S-(CH2)m-R b, -O-CHR a R b, -O-CR a(R b)2, -O-(CHR a)m-R b, -O- (CH2)m-CH[(CH2)m R b]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b, -S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHR a)m-R b, -NH-(CH2)m-R b, -NH-(CHR a)m-R b, -NH[(CH2)m R b], -N[(CH2)m R b]2, NH-C(O)-NH-(CH2)m-R b, NH-C(O)-(CH2)m-CHR b R b and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;
each R31, independently of the others, is methyl or (C1-C6) alkyl;
each R35 is, independently of the others, selected from the group consisting of hydrogen and R8, or, alternatively, two R35 bonded to the same carbon atom are taken together to form an oxo (=O), NH or NR38 group and the other two R35 are each, independently of one another, selected from the group consisting of hydrogen and R8;

each R36 is independently selected from the group consisting of hydrogen and (C1-C6) alkyl;
each R37 is independently selected from the group consisting of hydrogen and a progroup;
R38 is selected from the group consisting of (C1-C6) alkyl and (C5-C14) aryl;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d, (C1-C3) haloalkyloxy, -OCF3, =S, -SR d, NR d, NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR c R c, -S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R
d, -[NR a C(O)]n R d, -[NHC(O)]n OR d, -[NR a C(O)]n OR d, -[NHC(O)]n NR c R c, -[NR a C(O)]n NR c R c, -[NHC(NH)]n NR c R c and -[NR a C(NR a)]n NR c R c;
each R c is independently a protecting group or R a, or, alternatively, each R
c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently a protecting group or R a;
each m is independently an integer from 1 to 3;
each n is independently an integer from 0 to 3; and yy is 1 through 6.
2. The compound of Claim 1 in which R5 is fluoro.
3. The compound of Claim 2 in which R6 is hydrogen.
4. The compound of Claim 1 in which Y and Z are each, independently of one another, selected from the group consisting of O and NH.
5. The compound of Claim 4 in which X is CH.
6. The compound of Claim 5 in which Y and Z are each O.
7. The compound of Claim 6 in which each R35 is hydrogen.
8. The compound of Claim 5 in which Y is O and Z is NH.
9. A 2,4 pyrimidinediamine compound according to structure:
including salts, hydrates, solvates and N-oxides thereof, wherein:
L1 is a direct bond or a linker;
L2 is a direct bond or a linker;
R2 is a disubstituted phenyl group with two R b groups or R2 is a trisubstituted phenyl group with three R b groups;
R4 is X is selected from the group consisting of N and CH;
Y is selected from the group consisting of O, S, SO, SO2, SONR36, NH, NR35 and NR37;

Z is selected from the group consisting of O, S, SO, SO2, SONR36, NH, NR35 and NR37;
R5 is selected from the group consisting of R6, (C1-C6) alkyl optionally substituted with one or more of the same or different R8 groups, (C1-C4) alkanyl optionally substituted with one or more of the same or different R8 groups, (C2-C4) alkenyl optionally substituted with one or more of the same or different R8 groups and (C2-C4) alkynyl optionally substituted with one or more of the same or different R8 groups;
each R6 independently is selected from the group consisting of hydrogen, an electronegative group, -OR d, -SR d, (C1-C3) haloalkyloxy, (C1-C3) perhaloalkyloxy, -NR c R c, halogen, (C1-C3) haloalkyl, (C1-C3) perhaloalkyl, -CF3, -CH2CF3, -CF2CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR c R c; -S(O)2NR
c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)NR c R c, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -OC(O)R d, -SC(O)R d, -OC(O)OR d, -SC(O)OR d, -OC(O)NR c R c, -SC(O)NR c R c, -OC(NH)NR c R c, -SC(NH)NR c R c, -[NHC(O)]n R d, -[NHC(O)]n OR d, -[NHC(O)]n NR c R c and -[NHC(NH)]n NR c R c, (C5-C10) aryl optionally substituted with one or more of the same or different R8 groups, phenyl optionally substituted with one or more of the same or different R8 groups, (C6-C16) arylalkyl optionally substituted with one or more of the same or different R8 groups, 5-10 membered heteroaryl optionally substituted with one or more of the same or different R8 groups and 6-16 membered heteroarylalkyl optionally substituted with one or more of the same or different R8 groups;
R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b, -(CHR a)m-R b, -O-(CH2)m-R b, -S-(CH2)m-R b, -O-CHR a R b, -O-CR a(R b)2, -O-(CHR a)m-R b, -O- (CH2)m-CH[(CH2)m R b]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b, -S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHR a)m-R b, -NH-(CH2)m-R b, -NH-(CHR a)m-R b, -NH[(CH2)m-R b], -N[(CH2)m R b]2, -NH-C(O)-NH-(CH2)m-R b, -NH-C(O)-(CH2)m-CHR b R b and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;

each R35 is, independently of the others, selected from the group consisting of hydrogen and R8, or, alternatively, two R35 bonded to the same carbon atom are taken together to form an oxo (=O), NH or NR38 group and the other two R35 are each, independently of one another, selected from the group consisting of hydrogen and R8;
each R36 is independently selected from the group consisting of hydrogen and (C1-C6) alkyl;
each R37 is independently selected from the group consisting of hydrogen and a progroup;
R38 is selected from the group consisting of (C1-C6) alkyl and (C5-C14) aryl;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d, (C1-C3) haloalkyloxy, -OCF3, =S, -SR d, =NR d, NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR c R c, -S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R
d, -[NR a C(O)] n R d, -[NHC(O)]n OR d, -(NR a C(O)]n OR d, -[NHC(O)]n NR c R c, -[NR a C(O)]n NR c R c, -[NHC(NH)]n NR c R c and -[NR a C(NR a)]n NR c R c;
each R c is independently a protecting group or R a, or, alternatively, each R
c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently a protecting group or R a;
each m is independently an integer from 1 to 3; and each n is independently an integer from 0 to 3; with the provisio that N4-(2,2-Dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-N2-(3-chloro-4-methoxyphenyl)-5-fluoro-2,4-pyrimidinediamine;
N4-(2,2-Dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-N2-(3,5-dimethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine;
N2-(3,4-Dichlorophenyl)-N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-2,4-pyrimidinediamine;
N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-N2-(3-fluoro-4-methoxyphenyl)-5-fluoro-2,4-pyrimidinediamine;
N2-(3,5-Dichlorophenyl)-N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-2,4-pyrimidinediamine;
N2-(3-Chloro-4-trifluoromethoxyphenyl)-N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-2,4-pyrimidinediamine;
N2-(3-Chloro-4-methoxy-5-methylphenyl)-N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-2,4-pyrimidinediamine;
N2-(3-Chloro-4-hydroxy-5-methylphenyl)-N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-2,4-pyrimidinediamine; and N2-(3,5-Dimethyl-4-methoxyphenyl)-N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-2,4-pyrimidinediamine are not included.
10. A compound according to the structural formula:
and salts, hydrates, solvates, N-oxides and prodrugs thereof, wherein:
R2 is selected from the group consisting of (C1-C6) alkyl optionally substituted with one or more of the same or different R8 groups, (C3-C8) cycloalkyl optionally substituted with one or more of the same or different R8 groups, cyclohexyl optionally substituted with one or more of the same or different R8 groups, 3-8 membered cycloheteroalkyl optionally substituted with one or more of the same or different R8 groups, (C5-C15) aryl optionally substituted with one or more of the same or different R8 groups, phenyl optionally substituted with one or more of the same or different R8 groups and 5-15 membered heteroaryl optionally substituted with one or more of the same or different R8 groups;

R6a is (C5-C10) aryl optionally substituted with one or more of the same or different R8 groups or phenyl optionally substituted with one or more of the same or different R8 groups;
R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b, -(CHR a)m-R b, -O-(CH2)m-R b, -S-(CH2)m-R b, -O-CHR a R b, -O-CR a(R b)2, -O-(CHR a)m-R b, -O- (CH2)m-CH[(CH2)m R b]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b, -S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHR a)m-R b, -NH-(CH2)m-R b, -NH-(CHR a)m-R b, -NH[(CH2)m-R b], -N[(CH2)m-R b]2, -NH-C(O)-NH-(CH2)m-R b, -NH-C(O)-(CH2)m-CHR b R b and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d, (C1-C3) haloalkyloxy, -OCF3, =S, -SR d, NR d, NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR
c R c, -S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R
d, -[NR a C(O)]n R d, -[NHC(O)]n OR d, -(NR a C(O)]n OR d, -[NHC(O)]n NR c R c, -[NR a C(O)]n NR c R c, -[NHC(NH)]n NR c R c and -[NR a C(NR a)]n NR c R c;
each R c is independently R a, or, alternatively, each R c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which is optionally substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently R a;
each m is independently an integer from 1 to 3;
each n is independently an integer from 0 to 3;
R35 is a hydrogen or a suitable R8; and R45 is a (C3-C8) cycloalkyl optionally substituted with one or more of the same or different R8 groups.
11. A compound according to the structural formula:

and salts, hydrates, solvates and N-oxides thereof, wherein:

R2 is selected from the group consisting of wherein each R21 is independently a halogen atom or an alkyl optionally substituted with one or more of the same or different halo groups, R22 and R23 are each, independently of one another, a hydrogen atom, methyl or ethyl optionally substituted with one or more of the same or different halo groups;
R4 is a (C3-C8) cycloalkyl optionally substituted with one or more of the same or different R8 groups; and R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b, -(CHR a)m-R b, -O-(CH2)m R b, -S-(CH2)m-R b, -O-CHR a R b, -O-CR a (R b)2, -O-(CHR a)m-Rb, -O- (CH2)m CH[(CH2)m R b ]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b, -S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHR a)m-R b, -NH-(CH2)m-R b, -NH-(CHR a)m-R b,-NH[(CH2)m R
b], -N[(CH2)m R b]2, -NH-C(O)-NH-(CH2)m-R b, -NH-C(O)-(CH2)m-CHR b R b and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d,(C1-C3) haloalkyloxy, -OCF3, =S, -SR d, =NR d, =NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, -N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR
c R
-S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R
d, -[NR a C(O)]n R d, -[NHC(O)]n OR d, -[NR a C(O)]n OR d, -[NHC(O)]n NR c R c, -[NRaC(O)]n NR c R c, -[NHC(NH)]n NR c R c and -[NR a C(NR a)]n NR c R c;
each R c is independently R a, or, alternatively, each R c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which is optionally substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently R a;
each m is independently an integer from 1 to 3; and each h is independently an integer from 0 to 3.
12. A compound according to the structural formula:
and salts, hydrates, solvates and N-oxides thereof, wherein:
R2 is selected from the group consisting of (C1-C6) alkyl optionally substituted with one or more of the same or different R8 groups, (C3-C8) cycloalkyl optionally substituted with one or more of the same or different R8 groups, cyclohexyl optionally substituted with one or more of the same or different R8 groups, 3-8 membered cycloheteroalkyl optionally substituted with one or more of the same or different R8 groups, (C5-C15) aryl optionally substituted with one or more of the same or different R8 groups, phenyl optionally substituted with one or more of the same or different R8 groups and 5-15 membered heteroaryl optionally substituted with one or more of the same or different R8 groups;
R4 is selected from the group consisting of hydrogen, (C1-C6) alkyl optionally substituted with one or more of the same or different R8 groups, (C3-C8) cycloalkyl optionally substituted with one or more of the same or different R8 groups, cyclohexyl optionally substituted with one or more of the same or different R8 groups, 3-8 membered cycloheteroalkyl optionally substituted with one or more of the same or different R8 groups, (C5-C15) aryl optionally substituted with one or more of the same or different R8 groups, phenyl optionally substituted with one or more of the same or different R8 groups and 5-15 membered heteroaryl optionally substituted with one or more of the same or different R8 groups; and R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b,-(CHR a)m-R b, -O-(CH2)m-R b, -S-(CH2)m-R b, -O-CHR a R b, -O-CR a(R b)2, -O-(CHR a)m-R b, -O- (CH2)m-CH[(CH2)mR b]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b, -S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHR a)m-R b, -NH-(CH2)m-R b, -NH-(CHR a)m-R b, -NH[(CH2)mR
b], -N[(CH2)m R b]2, -NH-C(O)-NH-(CH2)m-R b, -NH-C(O)-(CH2)m-CHR b R b and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d,(C1-C3) haloalkyloxy, -OCF3, =S, -SR d,=NR d,=NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2,=N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR
c R c, -S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R
d, -[NR a C(O)]n R d, -[NHC(O)]n OR d, -[NR a C(O)]n OR d, -[NHC(O)]n NR c R c, -[NR a C(O)n NR c R c, -[NHC(NH)n NR c R c and -[NR a C(NR a)]n NR c R c;
each R c is independently R a, or, alternatively, each R c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which is optionally substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently R a;

each m is independently an integer from 1 to 3;
each h is independently an integer from 0 to 3; and R55 is selected from the group consisting of (C1-C6) alkyl optionally substituted with one or more of the same or different R8 groups, (C3-C8) cycloalkyl optionally substituted with one or more of the same or different R8 groups, cyclohexyl optionally substituted with one or more of the same or different R8 groups, 3-8 membered cycloheteroalkyl optionally substituted with one or more of the same or different R8 groups, (C5-C15) aryl optionally substituted with one or more of the same or different R8 groups, phenyl optionally substituted with one or more of the same or different R8 groups and 5-15 membered heteroaryl optionally substituted with one or more of the same or different R8 groups.
13. A compound according to the structural formula:
and salts, hydrates, solvates and N-oxides thereof, wherein:
R4 is selected from the group consisting of hydrogen, (C1-C6) alkyl optionally substituted with one or more of the same or different R8 groups, (C3-C8) cycloalkyl optionally substituted with one or more of the same or different R8 groups, cyclohexyl optionally substituted with one or more of the same or different R8 groups, 3-8 membered cycloheteroalkyl optionally substituted with one or more of the same or different R8 groups, (C5-C15) aryl optionally substituted with one or more of the same or different R8 groups, phenyl optionally substituted with one or more of the same or different R8 groups and 5-15 membered heteroaryl optionally substituted with one or more of the same or different R8 groups; and R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b, -(CHR a)m-R b, -O-(CH2)m-R b, -S-(CH2)m-R b, -O-CHR a R b, -O-CR a(R b)2, -O-(CHR a)m-R b, -O- (CH2)m-CH[(CH2)m R b]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b, -S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHR a)m-R b, -NH-(CH2)m-R b, -NH-(CHR a)m-R b, -NH[(CH2)m R b], -N[(CH2)m R b]2, -NH-C(O)-NH-(CH2)m-R b, -NH-C(O)-(CH2)m-CHR b R b and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d, (C1-C3) haloalkyloxy, -OCF3, =S, -SR d, NR d, NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR
c R c, -S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R
d, -[NR a C(O)]n R d, -[NHC(O)]n OR d, -[NR a C(O)]n OR d, -[NHC(O)]n NR c R c, -[NR a C(O)]n NR c R c, -[NHC(NH)]n NR c R c and -[NR a C(NR a)]n NR c R c;
each R c is independently R a, or, alternatively, each R c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which is optionally substituted with one or more of the same or different R a or suitable R b groups;
each R B is independently R a;

each m is independently an integer from 1 to 3;
each n is independently an integer from 0 to 3; and each R35 individually is a hydrogen or R8.
14. A 2,4-pyrimidinediamine compound according to structure:
and salts, hydrates, solvates and N-oxides thereof, wherein R2 is a phenyl group or indazole group, substituted with one or more of the same R8 groups;
R4 is R5 is a fluorine atom;
R6 is a hydrogen atom;
R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b, -(CHR a)m-R b, -O-(CH2)m-R b, -S-(CH2)m-R b, -O-CHR a R b, -O-CR a(R b)2, -O-(CHR a)m-R b, -O- (CH2)m-CH[(CH2)m R b]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b;
-S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHR a)m-R b, -NH-(CH2)m-R b, -NH-(CHR a)m-R b, -NH[(CH2)mR
b], -N[(CH2)m R b]2, -NH-C(O)-NH-(CH2)m-R b, -NH-C(O)-(CH2)m-CHR b R b and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d, (C1-C3) haloalkyloxy, =S, -SR d, =NR d, NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR c R
c, -S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R d, -[NR a C(O)]n R d, -[NHC(O)]n OR d, -[NR a C(O)]n OR d, -[NHC(O)]n NR c R c, -[NR a C(O)]n NR c R
c, -[NHC(NH)]n NR c R c and -[NR a C(NR a)]n NR c R c;
each R c is independently a protecting group or R a, or, alternatively, each R
c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R c or suitable R b groups;
each R d is independently an R a;
each m is independently an integer from 1 to 3; and each n is independently an integer from 0 to 3.
15. The compound of Claim 14 in which R2 is a di or tri substituted phenyl group.
16. The compound of Claim 15 in which one or more of the R8 groups are selected from the group consisting of halogens and alkoxy groups.
17. The compound of Claim 16 in which the 2,4-pyrimidinediamine compound is 1256, 1257, 1258, 1259 or 1260.
18. A 2,4-pyrimidinediamine compound according to structure:

and salts, hydrates, solvates and N-oxides thereof, wherein or phenyl substituted with one or more R8 groups;

R5 is a fluorine atom;
R6 is a hydrogen atom;
R11 and R12 are each, independently of one another, selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkoxy, aminoalkyl and hydroxyalkyl;
R35 is hydrogen or R8; and R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b, -(CHR a)m-R b, -O-(CH2)m-R b, -S-(CH2)m-R b, -O-CHR a R b, -O-CR a(R b)2, -O-(CHR a)m-R b, -O-(CH2)m-CH[(CH2)m R b]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b, -S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHR a)m-R b, NH-(CH2)m-R b, -NH-(CHR a)m-R b, -NH[(CH2)m R
b], -N((CH2)m R b]2, -NH-C(O)-NH-(CH2)m-R b, -NH-C(O)-(CH2)m-CHR b R b and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d, (C1-C3) haloalkyloxy, =S, -SR d, NR d, NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR c R
c, -S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R d, -[NR a C(O)n R d, -[NHC(O)]n OR d, -[NR a C(O)n OR d, -LNHC(O)n NR c R c, -LNR a C(O)]n NR c R
c, -[NHC(NH)n NR c R c and -[NR a C(NR a)]n NR c R c;
each R c is independently a protecting group or R a, or, alternatively, each R
c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently an R a;
each m is independently an integer from 1 to 3; and each n is independently an integer from 0 to 3.
19. The compound of claim 18 in which R35 is not a methyl group.
20. The compound of Claim 18 in which the 2,4-pyrimidinediamine compound is 1000, 1001 or 1002..
21. A 2,4-pyrimidinediamine compound according to structure:
and salts, hydrates, solvates and N-oxides thereof, wherein R2 is R4 is R5 is a fluorine atom;
R6 is a hydrogen atom;
Y is selected from the group consisting of O, S, SO, SO2, SONR36, NH and NR37;
Z is selected from the group consisting of O, S, SO, SO2, SONR36, NH and NR37;
eac R35 is, independently of the others, selected from the group consisting of hydrogen and R8, or, alternatively, two R35 bonded to the same carbon atom are taken together to form an oxo (=O), NH or NR38 group and the other two R35 each, independently of one another, are selected from the group consisting of hydrogen and R8;
R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b, -(CHR a)m-R b, -O-(CH2)m-R b, -S-(CH2)m-2R b, -O-CHR a R b, -O-CR a(R b)2, -O-(CHR a)m-R b, -O- (CH2)m-CH[(CH2)m R b]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b, -S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHR a)m-R b, -NH-(CH2)m-R b, NH-(CHR a)m-R b, -NH[(CH2)m R
b], -N[(CH2)m R b]2, -NH-C(O)-NH-(CH2)m-R b, -NH-C(O)-(CH2)m-CHR b R b and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d, (C1-C3) haloalkyloxy, =S, -SR d, NR d, NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR c R
c, -S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R d, -[NR a C(O)n R d, -[NHC(O)n OR d, -(NR a C(O)n OR d, -[NHC(O)n NR c R c, -LNR a C(O)n NR c R c, -[NHC(NH)]n NR c R c and -[NR a C(NR a)]n NR c R c;
each R c is independently a protecting group or R a, or, alternatively, each R
c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently an R a;
each m is independently an integer from 1 to 3;
each n is independently an integer from 0 to 3;
R36 is hydrogen or alkyl; and R37 is selected from the group consisting of hydrogen and a progroup.
22. The compound of Claim 21 in which Y is oxygen, Z is NH and one or more R35 is an alkyl group.
23. The compound of Claim 21 in which R4 is
24. The compound of Claim 21 in which R4 is
25. The compound of Claim 21 in which Y is oxygen, Z is NH.
26. The compound of Claim 21 in which the 2,4-pyrimidinediamine compound is 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 1281, 1283, 1283, 1284, 1285, 1287, 1288, 1289, 1290 or 1291.
27. A 2,4-pyrimidinediamine compound according to structure:
and salts, hydrates, solvates and N-oxides thereof, wherein R2 is is wherein Y is O, S, SO, SO2, SONR36, NH, NR37; or NR35;
R4 is selected from the group consisting of (C1-C6) alkyl optionally substituted with one or more of the same or different R8 groups, (C3-C8) cycloalkyl optionally substituted with one or more of the same or different R8 groups, cyclohexyl optionally substituted with one or more of the same or different R8 groups, 3-8 membered cycloheteroalkyl optionally substituted with one or more of the same or different R8 groups, (C5-C15) aryl optionally substituted with one or more of the same or different R8 groups, phenyl optionally substituted with one or more of the same or different R8 groups and 5-15 membered heteroaryl optionally substituted with one or more of the same or different R8 groups;
R5 is a fluorine atom;
R6 is a hydrogen atom;
R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b, -(CHR a)m-R b, -O-(CH2)m-R b, -S-(CH2)m-R b, -O-CHR a R b, -O-CR a(R b)2, -O-(CHR a)m-R b, -O- (CH2)m-CH[(CH2)m R b]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b, -S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHRa )m-R b, -NH-(CH2)m-R b, -NH-(CHR a)m-R b, -NH[(CH2)m-R b], -N[(CH2)m R b]2, -NH-C(O)-NH-(CH2)m-R b, -NH-C(O)-(CH2)m-CHR b R b and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d, (C1-C3) haloalkyloxy, =S, -SR d, NR d, =NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR c R
c, -S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c; -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R d, -[NR a C(O)]n R d, -(NHC(O)]n OR d, -[NR a C(O)]n OR d, -(NHC(O)]n NR c R c, -[NR a C(O)]n NR c R
c, -[NHC(NH)]n NR c R c and -[NR a C(NR a)n NR c R c;
each R c is independently a protecting group or R a, or, alternatively, each R
c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently an R a;
each m is independently an integer from 1 to 3;
each n is independently an integer from 0 to 3;
R35 is hydrogen or R8;
R36 is hydrogen or alkyl; and R37 is selected from the group consisting of hydrogen and a progroup
28. The compound of Claim 27 in which the 2,4-pyrimidinediamine compound is 1070, 1071, 1073, 1074, 1075, 1076, 1078, 1080, 1085, 1091 or 1092.
29. A 2, 4-pyrimidinediamine compound according to structure:

and salts, hydrates, solvates and N-oxides thereof, wherein R2 is selected from the group consisting of (C1-C6) alkyl optionally substituted with one or more of the same or different R8 groups, (C3-C8) cycloalkyl optionally substituted with one or more of the same or different R8 groups, cyclohexyl optionally substituted with one or more of the same or different R8 groups, 3-8 membered cycloheteroalkyl optionally substituted with one or more of the same or different R8 groups, (C5-C15) aryl optionally substituted with one or more of the same or different R8 groups, phenyl optionally substituted with one or more of the same or different R8 groups and 5-15 membered heteroaryl optionally substituted with one or more of the same or different R8 groups;
R4 is R5 is a fluorine atom;
R6 is a hydrogen atom; and R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b, -(CHR a)m-R b, -O-(CH2)m-R b, -S-(CH2)m-R b, -O-CHR a R b, -O-CR a(R b)2, -O-(CHR a)m-R b, -O- (CH2)m-CH[(CH2)m R b]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b, -S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHR a)m-R b, -NH-(CH2)m-R b, -NH-(CHR a)m-R b, -NH[(CH2)m R b], -N[(CH2)m-R b]2, -NH-C(O)-NH-(CH2)m-R b, -NH-C(O)-(CH2)m-CHR b R b and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d, (C1-C3) haloalkyloxy, -OCF3, =S, -SR d, NR d, NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, NO2, N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR c R c, -S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R
d, -[NR a C(O)]n R d, -[NHC(O)n OR d, -[NR a C(O)]n OR d, -(NHC(O)]n NR c R c, -[NR a C(O)]n NR c R c, -(NHC(NH)]n NR c R c and -(NR a C(NR a)]n NR c R c;
each R c is independently a protecting group or R a, or, alternatively, each R
c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently a protecting group or R a;
each m is independently an integer from 1 to 3; and each n is independently an integer from 0 to 3.
30. The compound of Claim 29 in which R2 is , and each R46, R47 and R48 independently is selected from the group consisting of a hydrogen, alkyl, alkoxy, hydroxyl, halogen, isoxazole, piperazino, N-alkyl piperazine, morpholino and CH3NHC(O)CH2O-, with the proviso that R46, R47 and R48 are all not hydrogen and when one of R46, R47 or R48 is isoxazole, piperazino, N-alkyl piperazine, morpholino or CH3NHC(O)CH2O-, then the remaining R46, R47 or R48 are hydrogen.
31. The compound of Claim 29 in which R2 is selected from the group consisting of each R21, R22 and R23 are each, independently of one another, an alkyl group.
32. The compound of claim 31 in which R22 and R23 or R21 and R22 or R21, R22 and R23 are each methyl groups.
33. A 2, 4-pyrimidinediamine compound according to structure:
and salts, hydrates, solvates and N-oxides thereof, wherein R4 is selected from the group consisting of R5 is a fluorine atom;
R6 is a hydrogen atom;
R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b, -(CHR a)m-R b, -O-(CH2)m-R b, -S-(CH2)m-R b, -O-CHR a R b, -O-CR a(R b)2, -O-(CHR a)m-R b, -O- (CH2)m-CH((CH2)m R b]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b, -S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHR a)m-R b, -NH-(CH2)m-R b, -NH-(CHR a)m-R b, -NH[(CH2)m R b], -N[(CH2)m R b]2, -NH-C(O)-NH-(CH2)m-R b, -NH-C(O)-(CH2)m-CHRbRb and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;
R21 is an alkyl group;
R23 is an alkyl group;
each R28 individually is a halogen or alkoxy;
R29 is a (C1-C6) alkyl or (C3-C9) cycloalkyl;
X is selected from the group consisting of N and CH
Y is selected from the group consisting of O, S, SO, SO2, SONR36, NH and NR37;
Z is selected from the group consisting of O, S, SO, SO2, SONR36, NH and NR37;

each R35 is, independently of the others, selected from the group consisting of hydrogen and R8, or, alternatively, two R35 bonded to the same carbon atom are taken together to form an oxo (=O), NH or NR3$ group and the other two R35 each, independently of one another , are selected from the group consisting of hydrogen and R8;
each R36 is independently selected from the group consisting of hydrogen and (C1-C6) alkyl;
each R37 is independently selected from the group consisting of hydrogen and a progroup;
R38 is selected from the group consisting of (C1-C6) alkyl and (C5-C14) aryl;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d, (C1-C3) haloalkyloxy, -OCF3, =S, -SR d, NR d, NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR
c R c, -S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R
d, -[NR a C(O)]n R d, -[NHC(O)]n OR d, -[NR a C(O)n OR d, -[NHC(O)]n NR c R c, -[NR a C(O)]n NR c R c, -[NHC(NH)]n NR c R c and -[NR a C(NR a)]n NR c R c;
each R c is independently a protecting group or R a, or, alternatively, each R
c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently a protecting group or R a;
each m is independently an integer from 1 to 3; and each n is independently an integer from 0 to 3.
34. The compound of claim 33 in which R28 is a methoxy.
35. The compound of claim 33 in which R21 is a methyl group.
36. The compound of claim 33 in which each R28 is a chlorine.
37. The compound of claim 33 in which R21 is a methyl group and R28 is a chlorine.
38. A 2, 4-pyrimidinediamine compound according to structure:
and salts, hydrates, solvates and N-oxides thereof, wherein R4 is selected from the group consisting of R5 is a fluorine atom;
R6 is a hydrogen atom;
R8 is selected from the group consisting of R a, R b, R a substituted with one or more of the same or different R a or R b, -OR a substituted with one or more of the same or different R a or R b, -B(OR a)2, -B(NR c R c)2, -(CH2)m-R b, -(CHR a)m-R b, -O-(CH2)m-R b, -S-(CH2)m-R b, -O-CHR a R b, -O-CR a(R b)2, -O-(CHR a)m-R b, -O-(CH2)m-CH[(CH2)m R b]R b, -S-(CHR a)m-R b, -C(O)NH-(CH2)m-R b, -C(O)NH-(CHR a)m-R b, -O-(CH2)m-C(O)NH-(CH2)m-R b, -S-(CH2)m-C(O)NH-(CH2)m-R b, -O-(CHR a)m-C(O)NH-(CHR a)m-R b, -S-(CHR a)m-C(O)NH-(CHR a)m-R b, -NH-(CH2)m-R b, NH-(CHR a)m-R b, NH[(CH2)m R
b], -N[(CH2)m R b]2, -NH-C(O)-NH-(CH2)m-R b, -NH-C(O)-(CH2)m-CHR b R b and -NH-(CH2)m-C(O)-NH-(CH2)m-R b;
R21 is an alkyl group;
each R28 individually is a halogen or alkoxy;
X is selected from the group consisting of N and CH
Y is selected from the group consisting of O, S, SO, SO2, SONR36, NH and NR37;
Z is selected from the group consisting of O, S, SO, SO2, SONR36, NH and NR37;
each R35 is, independently of the others, selected from the group consisting of hydrogen and R8, or, alternatively, two R35 bonded to the same carbon atom are taken together to form an oxo (=O), NH or NR38 group and the other two R35 each, independently of one another , are selected from the group consisting of hydrogen and R8;
each R36 is independently selected from the group consisting of hydrogen and (C1-C6) alkyl;
each R37 is independently selected from the group consisting of hydrogen and a progroup;
R38 is selected from the group consisting of (C1-C6) alkyl and (C5-C14) aryl;
each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each R b is a suitable group independently selected from the group consisting of =O, -OR d, (C1-C3) haloalkyloxy, -OCF3, =S, -SR d, NR d, NOR d, -NR c R c, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)R d, -S(O)2R d, -S(O)2OR d, -S(O)NR
c R c, -S(O)2NR c R c, -OS(O)R d, -OS(O)2R d, -OS(O)2OR d, -OS(O)2NR c R c, -C(O)R d, -C(O)OR d, -C(O)NR c R c, -C(NH)NR c R c, -C(NR a)NR c R c, -C(NOH)R a, -C(NOH)NR c R c, -OC(O)R d, -OC(O)OR d, -OC(O)NR c R c, -OC(NH)NR c R c, -OC(NR a)NR c R c, -[NHC(O)]n R
d, -[NRaC(O)]n R d, -[NHC(O)]n OR d, -[NR a C(O)]n OR d, -[NHC(O)]n NR c R c, -[NR a C(O)]n NR c R c, -[NHC(NH)]n NR c R c and -[NR a C(NR a)]n NR c R c;
each R c is independently a protecting group or R a, or, alternatively, each R
c is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R a or suitable R b groups;
each R d is independently a protecting group or R a;
each m is independently an integer from 1 to 3;
each n is independently an integer from 0 to 3;
p is 1, 2 or 3;
R50 is an alkyl group or -(CH2)q OH;
q is an integer from 1 to 6; and R52 is an alkyl group or a substituted alkyl group.
39. The compound of claim 38 in which R21 is a methyl group.
40. The compound of claim 38 in which each R28 is a chlorine.
41. The compound of claim 38 in which R21 is a methyl group and R28 is a chlorine.
42. The compound of claim 38 in which R50 is -CH2CH2OH.
43. The compound of claim 38 in which R52 is trifluoromethyl.
44. The compound of claim 38 in which R50 is a methyl group.
45. The compound of claim 38 in which each R28 is a chlorine.
46. The compound of claim 38 in which R50 is a methyl group and R28 is a chlorine.
47. A 2, 4-pyrimidinediamine compound according to structure:

and salts, hydrates, solvates and N-oxides thereof, wherein R2 is R4 is a cycloalkyl;
R5 is a fluorine atom;
R6 is a hydrogen atom;
R21 is an alkyl group; and R30 is an alkyl group or a halogen.
48. The compound of claim 47 in which R21 is a methyl group.
49. The compound of any one of Claims 1-48 further comprising a pharmaceutically acceptable carrier, diluent or excipient.
50. A method of treating or preventing an autoimmune disease and/or one or more symptoms associated therewith, comprising the step of administering to a subject suffering from an autoimmune disease or at risk of developing an autoimmune disease an effective amount of a 2,4-pyrimidinediamine compound according to any one of Claims 1-49.
CA2533377A 2003-07-30 2004-07-30 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds Active CA2533377C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US49164103P 2003-07-30 2003-07-30
US60/491,641 2003-07-30
US53159803P 2003-12-19 2003-12-19
US60/531,598 2003-12-19
US57224604P 2004-05-18 2004-05-18
US60/572,246 2004-05-18
PCT/US2004/024716 WO2005016893A2 (en) 2003-07-30 2004-07-30 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases

Publications (2)

Publication Number Publication Date
CA2533377A1 true CA2533377A1 (en) 2005-02-24
CA2533377C CA2533377C (en) 2012-11-27

Family

ID=34119815

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2533377A Active CA2533377C (en) 2003-07-30 2004-07-30 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Country Status (22)

Country Link
US (10) US8178671B2 (en)
EP (1) EP1656372B1 (en)
JP (2) JP4886511B2 (en)
KR (2) KR101201603B1 (en)
CN (2) CN102358738A (en)
AU (2) AU2004265288A1 (en)
BR (1) BRPI0413018B8 (en)
CA (1) CA2533377C (en)
CY (1) CY1114445T1 (en)
DK (1) DK1656372T3 (en)
ES (1) ES2421139T3 (en)
HK (1) HK1091209A1 (en)
HR (1) HRP20130602T1 (en)
IL (1) IL173299A (en)
NO (1) NO333771B1 (en)
NZ (1) NZ545270A (en)
PL (1) PL1656372T3 (en)
PT (1) PT1656372E (en)
RS (1) RS53109B (en)
SG (1) SG145698A1 (en)
WO (2) WO2005016893A2 (en)
ZA (1) ZA200601460B (en)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2337782T3 (en) * 2002-07-29 2010-04-29 Rigel Pharmaceuticals, Inc. METHODS TO TREAT OR PREVENT AUTOIMMUNITY DISEASES WITH 2,4-PYRIMIDINDIAMINE COMPOUNDS.
NZ545270A (en) * 2003-07-30 2010-04-30 Rigel Pharmaceuticals Inc 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
DE602004032446D1 (en) * 2003-08-07 2011-06-09 Rigel Pharmaceuticals Inc 2,4-PYRIMIDINDIAMIN COMPOUNDS AND USES AS ANTIPROLIFERATIVE AGENTS
CA2566531A1 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070232659A1 (en) * 2004-06-18 2007-10-04 Dan Peters Novel Alkyl Substituted Piperidine Derivatives as Monoamine Neurotransmitter Re-Uptake Inhibitors
WO2006004776A1 (en) * 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. 4-pyrimidineamine compounds and their uses as anti-proliferative agents
EP1786783A1 (en) * 2004-09-01 2007-05-23 Rigel Pharmaceuticals, Inc. Synthesis of 2,4-pyrimidinediamine compounds
EP1794135A1 (en) * 2004-09-27 2007-06-13 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
ES2380550T3 (en) * 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Spiro-2,4-pyrimidinediamine compounds and their uses
KR101278397B1 (en) 2005-01-19 2013-06-25 리겔 파마슈티칼스, 인크. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
MX2007009437A (en) 2005-02-04 2007-08-16 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors.
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
WO2007027238A2 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2651349T3 (en) 2005-06-08 2018-01-25 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibiting the JAK route
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
PL1734251T3 (en) * 2005-06-17 2007-05-31 Magneti Marelli Powertrain Spa Fuel injector
WO2007053844A2 (en) * 2005-10-31 2007-05-10 Rigel Pharmaceuticals, Inc. Compositions and methods for treating inflammatory disorders
KR101467723B1 (en) * 2005-11-01 2014-12-03 탈자진 인코포레이티드 Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US7713987B2 (en) * 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
EP1968950A4 (en) * 2005-12-19 2010-04-28 Genentech Inc Pyrimidine kinase inhibitors
WO2007085540A1 (en) * 2006-01-27 2007-08-02 Glaxo Group Limited 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
PL1984357T3 (en) 2006-02-17 2014-03-31 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
JP2009528295A (en) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Compositions and methods for inhibition of the JAK pathway
EP2054392A2 (en) * 2006-06-15 2009-05-06 Boehringer Ingelheim International GmbH 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
KR20090023698A (en) 2006-06-15 2009-03-05 베링거 인겔하임 인터내셔날 게엠베하 2-anilino-4-aminoalkyleneaminopyrimidines
CA2673125C (en) * 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
MX2009004426A (en) 2006-10-23 2009-08-12 Cephalon Inc Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors.
ES2380551T3 (en) 2006-11-21 2012-05-16 Rigel Pharmaceuticals, Inc. Prodrug salts of 2,4-pyrimidinediamine compounds and their uses
EP1939185A1 (en) * 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft New types of hetaryl-phenylendiamin-pyrimidines as protein kinase inhibitors for the treatment of cancer
DE102007010801A1 (en) 2007-03-02 2008-09-04 Bayer Cropscience Ag Use of new and known 2,4-diaminopyrimidine derivatives as fungicides, especially for controlling phytopathogenic fungi
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2008118823A2 (en) * 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2705599T3 (en) * 2007-04-16 2019-03-26 Abbvie Inc Indoles substituted in position 7 as inhibitors of mcl-1
AU2008275918B2 (en) 2007-07-17 2014-01-30 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
WO2009032668A2 (en) 2007-08-28 2009-03-12 Irm Llc 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
EP2215087B1 (en) 2007-09-05 2013-12-18 Rigel Pharmaceuticals, Inc. Xinafoate salt of n4- (2,2-difluoro-4h-benzo [1,4] oxazin-3-one) - 6-yl] - 5-fluoro-n2 - [3-(methylaminocarbonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine
KR101700454B1 (en) 2008-02-15 2017-01-26 리겔 파마슈티칼스, 인크. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
US8592432B2 (en) 2008-04-07 2013-11-26 Bei Chen Compounds and compositions as protein kinase inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
SG165655A1 (en) 2008-04-16 2010-11-29 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
US8063058B2 (en) * 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
BRPI0910668A2 (en) * 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc protein kinase inhibitors
AU2009248923B2 (en) 2008-05-21 2015-01-29 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
MX2010014568A (en) * 2008-06-25 2011-03-29 Irm Llc Pyrimidine derivatives as kinase inhibitors.
UY31929A (en) 2008-06-25 2010-01-05 Irm Llc COMPOUNDS AND COMPOSITIONS AS CINASE INHIBITORS
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
RU2536584C2 (en) 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Heteroaryl compounds and using them
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2161259A1 (en) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Haloalkyl substituted Diaminopyrimidine
WO2010027002A1 (en) * 2008-09-05 2010-03-11 塩野義製薬株式会社 Ring-fused morpholine derivative having pi3k-inhibiting activity
CA2746810C (en) 2008-12-30 2017-03-14 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
JP5781942B2 (en) * 2009-01-14 2015-09-24 ライジェル ファーマシューティカルズ， インコーポレイテッド Method for treating inflammatory disorders using 2,4-pyrimidinediamine compounds
CA2749195C (en) * 2009-01-15 2017-03-07 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
JP5781943B2 (en) * 2009-01-21 2015-09-24 ライジェル ファーマシューティカルズ， インコーポレイテッド N2- (3-pyridyl or phenyl) -N4- (4-piperidyl) -2,4-pyrimidinediamine derivatives useful for the treatment of inflammatory diseases, autoimmune diseases or proliferative diseases
PT2389372E (en) * 2009-01-23 2016-01-07 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
TW201040162A (en) 2009-05-06 2010-11-16 Portola Pharm Inc Inhibitors of JAK
UA108077C2 (en) 2009-07-02 2015-03-25 SYNTHESIS OF DINODIUM SALT N4- (2,2-DIMETHYL-4 - $ (DYHYDROPHOPHONOXY) METHYL] -3-OXO-5-PYRIDO $ 1,4] OXAZIN-6-YL) -2-FLUORINE 5-TRIMETHOXYPHENYL) -2,4-PYRIMIDINDIAMINE
EP2454265A2 (en) 2009-07-17 2012-05-23 Rigel Pharmaceuticals, Inc. Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
JP5738292B2 (en) * 2009-07-28 2015-06-24 ライジェル ファーマシューティカルズ， インコーポレイテッド Compositions and methods for inhibition of the JAK pathway
US8592129B2 (en) * 2009-08-31 2013-11-26 Sumitomo Chemical Company, Limited Resin, resist composition and method for producing resist pattern
EP2501705B1 (en) 2009-11-20 2014-08-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
US20110130415A1 (en) * 2009-12-01 2011-06-02 Rajinder Singh Protein kinase c inhibitors and uses thereof
MX2012007402A (en) 2009-12-23 2012-08-23 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors.
JP2013519732A (en) 2010-02-17 2013-05-30 アムジエン・インコーポレーテツド Arylcarboxamide derivatives as sodium channel inhibitors for the treatment of pain
EP2558474B1 (en) 2010-04-13 2015-11-25 Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
CN103003264B (en) 2010-05-21 2014-08-06 切米利亚股份公司 Novel pyrimidine derivatives
RS54865B1 (en) 2010-06-04 2016-10-31 Hoffmann La Roche Aminopyrimidine derivatives as lrrk2 modulators
WO2012012619A1 (en) 2010-07-21 2012-01-26 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
MX347331B (en) 2010-07-28 2017-04-21 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway.
US9063414B2 (en) 2010-07-28 2015-06-23 Sumitomo Chemical Company, Limited Photoresist composition
SG187796A1 (en) 2010-08-10 2013-03-28 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
JP6195692B2 (en) 2010-08-30 2017-09-13 住友化学株式会社 RESIST COMPOSITION, METHOD FOR PRODUCING RESIST PATTERN, NOVEL COMPOUND AND RESIN
JP2012102088A (en) * 2010-10-14 2012-05-31 Sumitomo Chemical Co Ltd Heteroaromatic ring compound and use thereof for pest control
US10028975B2 (en) 2010-10-19 2018-07-24 Beth Israel Deaconess Medical Center, Inc. Methods for treating ischemia-reperfusion injury
CA2816219C (en) 2010-11-01 2019-10-29 Portola Pharmaceuticals, Inc. Nicotinamides as syk modulators
JP5956999B2 (en) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Heteroaryl compounds and uses thereof
EP2635557A2 (en) 2010-11-01 2013-09-11 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US20130317029A1 (en) 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
TWI632134B (en) 2010-11-01 2018-08-11 阿維拉製藥公司 Heterocyclic compounds and uses thereof
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
PT3124483T (en) * 2010-11-10 2019-10-02 Genentech Inc Pyrazole aminopyrimidine derivatives as lrrk2 modulators
JP5879834B2 (en) 2010-11-15 2016-03-08 住友化学株式会社 Salt, resist composition and method for producing resist pattern
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
JP5947053B2 (en) 2011-02-25 2016-07-06 住友化学株式会社 Resist composition and method for producing resist pattern
JP6034025B2 (en) 2011-02-25 2016-11-30 住友化学株式会社 Resist composition and method for producing resist pattern
JP5898520B2 (en) 2011-02-25 2016-04-06 住友化学株式会社 Resist composition and method for producing resist pattern
JP5829939B2 (en) 2011-02-25 2015-12-09 住友化学株式会社 Resist composition and method for producing resist pattern
JP6034026B2 (en) 2011-02-25 2016-11-30 住友化学株式会社 Resist composition and method for producing resist pattern
JP5829940B2 (en) 2011-02-25 2015-12-09 住友化学株式会社 Resist composition and method for producing resist pattern
JP5898521B2 (en) 2011-02-25 2016-04-06 住友化学株式会社 Resist composition and method for producing resist pattern
JP5947051B2 (en) 2011-02-25 2016-07-06 住友化学株式会社 Resist composition and method for producing resist pattern
JP5829941B2 (en) 2011-02-25 2015-12-09 住友化学株式会社 Resist composition and method for producing resist pattern
ES2587864T3 (en) 2011-03-24 2016-10-27 Noviga Research Ab Pyrimidine derivatives
KR101884010B1 (en) 2011-05-04 2018-07-31 어리어드 파마슈티칼스, 인코포레이티드 Compounds for inhibiting cell proliferation in egfr-driven cancers
RU2013154412A (en) 2011-05-10 2015-06-20 Мерк Шарп И Доум Корп. AMINOPYRIMIDINES AS SYC INHIBITORS
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
WO2012177714A1 (en) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
JP5977594B2 (en) 2011-07-19 2016-08-24 住友化学株式会社 Resist composition and method for producing resist pattern
JP6130630B2 (en) 2011-07-19 2017-05-17 住友化学株式会社 Resist composition and method for producing resist pattern
JP6013799B2 (en) 2011-07-19 2016-10-25 住友化学株式会社 Resist composition and method for producing resist pattern
JP6189020B2 (en) 2011-07-19 2017-08-30 住友化学株式会社 Resist composition and method for producing resist pattern
JP6013798B2 (en) 2011-07-19 2016-10-25 住友化学株式会社 Resist composition and method for producing resist pattern
JP5977595B2 (en) 2011-07-19 2016-08-24 住友化学株式会社 Resist composition and method for producing resist pattern
JP5985898B2 (en) 2011-07-19 2016-09-06 住友化学株式会社 Resist composition and method for producing resist pattern
JP5912912B2 (en) 2011-07-19 2016-04-27 住友化学株式会社 Resist composition and method for producing resist pattern
JP5996944B2 (en) 2011-07-19 2016-09-21 住友化学株式会社 Resist composition and method for producing resist pattern
JP6130631B2 (en) 2011-07-19 2017-05-17 住友化学株式会社 Resist composition and method for producing resist pattern
JP5977593B2 (en) 2011-07-19 2016-08-24 住友化学株式会社 Resist composition and method for producing resist pattern
JP6013797B2 (en) 2011-07-19 2016-10-25 住友化学株式会社 Resist composition and method for producing resist pattern
JP5886696B2 (en) 2011-07-19 2016-03-16 住友化学株式会社 Resist composition and method for producing resist pattern
JP5990041B2 (en) 2011-07-19 2016-09-07 住友化学株式会社 Resist composition and method for producing resist pattern
ES2710423T3 (en) 2011-07-28 2019-04-25 Rigel Pharmaceuticals Inc New (trimethoxyphenylamino) pyrimidinyl formulations
US8729079B2 (en) 2011-08-23 2014-05-20 Endo Pharmaceuticals Inc. Pyrimido-pyridazinone compounds and methods of use thereof
US9221798B2 (en) * 2011-09-05 2015-12-29 Zhejian Hisun Pharmaceutical Co., Ltd. 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof
WO2013052393A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9006444B2 (en) 2011-10-05 2015-04-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
TW201325593A (en) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc Methods of treating a BRUTON'S tyrosine kinase disease or disorder
KR102019530B1 (en) 2011-11-23 2019-09-06 포톨라 파마슈티컬스, 인코포레이티드 Pyrazine kinase inhibitors
AU2012370450B2 (en) * 2012-02-21 2017-02-02 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
SG11201405691WA (en) 2012-03-15 2014-10-30 Celgene Avilomics Res Inc Solid forms of an epidermal growth factor receptor kinase inhibitor
PT2825042T (en) 2012-03-15 2018-11-16 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
US9487504B2 (en) 2012-06-20 2016-11-08 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
EP2863914B1 (en) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
WO2013192098A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2863915B1 (en) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
KR101446742B1 (en) 2012-08-10 2014-10-01 한국화학연구원 N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine derivatives or pharmaceutically acceptable salt thereof, and pharmaceutical composition for the prevention or treatment of cancer containing the same as an active ingredient
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc Substituted pyrimidinyl kinase inhibitors
US9062068B2 (en) 2012-12-04 2015-06-23 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
WO2014093191A1 (en) 2012-12-12 2014-06-19 Merck Sharp & Dohme Corp. AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2014100314A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
CA2899281C (en) 2013-01-25 2022-05-31 Rigel Pharmaceuticals, Inc. Pyrimidinediamine compounds for use in treating or preventing autoimmune alopecia
ES2805359T3 (en) 2013-02-08 2021-02-11 Celgene Car Llc ERK inhibitors and their uses
US9169249B2 (en) 2013-03-14 2015-10-27 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014176210A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
RS58084B1 (en) 2013-12-20 2019-02-28 Rigel Pharmaceuticals Inc Pharmaceutical process and intermediates
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
CN104926794B (en) * 2014-03-17 2017-12-05 广东东阳光药业有限公司 Substituted heteroaryl compound and combinations thereof and purposes
JP6517319B2 (en) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ Substituted heteroaryl compounds and methods of use
CN105017159B (en) * 2014-04-28 2019-05-17 四川大学 Fluoro- 2,4- disubstituted amido pyrimidine derivatives of 5- and its preparation method and application
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
WO2016172053A1 (en) 2015-04-24 2016-10-27 Rigel Pharmaceuticals, Inc. Methods of treating ibrutinib-resistant disease
ES2854703T3 (en) * 2015-07-09 2021-09-22 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
US10478237B2 (en) 2016-01-04 2019-11-19 OsteoCertus, LLC Orthopedic bone plate system
US10939943B2 (en) 2016-01-04 2021-03-09 OsteoCertus, LLC Orthopedic bone plate system
US10258402B2 (en) 2016-01-04 2019-04-16 OsteoCertus, LLC Orthopedic bone plate system
US11203576B2 (en) * 2016-03-11 2021-12-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
RU2621187C1 (en) * 2016-05-13 2017-06-01 Общество с ограниченной ответственностью "Молекулярные Технологии" New crystalline salt form of 2,2-dimethyl-6-((4-((3,4,5-trimethoxyphenyl)amino)-1,3,5-triazin-2-yl)amino)-2h-pyrido[3,2-b][1,4]oxazin-3(4h)-one for medical use
CA3079292A1 (en) 2017-10-19 2019-04-25 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
TW202108573A (en) 2019-05-10 2021-03-01 美商迪賽孚爾製藥有限公司 Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
RS64755B1 (en) 2019-05-10 2023-11-30 Deciphera Pharmaceuticals Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
EP3983081A1 (en) 2019-06-17 2022-04-20 Deciphera Pharmaceuticals, LLC Aminopyrimidine amide autophagy inhibitors and methods of use thereof
WO2021026451A1 (en) 2019-08-08 2021-02-11 Rigel Pharmaceuticals, Inc. Compounds and method for treating cytokine release syndrome
MX2022001890A (en) 2019-08-14 2022-04-26 Rigel Pharmaceuticals Inc Method of blocking or ameliorating cytokine release syndrome.

Family Cites Families (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3159547A (en) * 1963-06-28 1964-12-01 Abbott Lab Method of lowering blood pressure with 4-(2-amino-4-pyrimidylamino)-benzene-sulfonamide
US3320256A (en) 1965-04-09 1967-05-16 Hoffmann La Roche Fluorinated imidazoo[1, 2-c]pyrimidines and pyrimido[1, 2-c]pyrimidines
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GR80171B (en) 1983-08-29 1985-01-02 Ciba Geigy Ag N-(2-nitrophenyl)-4-aminopyrimidine derivatives process for the preparation thereof and use
HU192875B (en) 1984-10-05 1987-07-28 Richter Gedeon Vegyeszet Process for preparing 2-pyridinethiol derivatives
AU603340B2 (en) * 1985-08-02 1990-11-15 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Novel vitamin d analogues
DE3618353A1 (en) 1986-05-31 1987-12-03 Hoechst Ag PEST CONTROLS BASED ON AMINOPYRIMIDINE DERIVATIVES AND NEW AMINOPYRIMIDINE COMPOUNDS
DE3868287D1 (en) 1987-04-02 1992-03-19 Ciba Geigy Ag REACTIVE DYES, THEIR PRODUCTION AND USE.
SU1499883A1 (en) 1987-11-24 1991-10-23 Научно-исследовательский институт фармакологии АМН СССР Dichlorhydrate 2,4-bis-(p-tret-butylanilino)-5-oxi-6-methylpyrimidine possessing analsetyc and antiflammatory activity
AU614372B2 (en) * 1988-04-21 1991-08-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Novel vitamin d analogues
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US4969781A (en) * 1989-04-07 1990-11-13 The B. F. Goodrich Company Blind fastener hand tool
IE63502B1 (en) * 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
US5179204A (en) 1989-09-05 1993-01-12 Hoechst-Roussel Pharmaceuticals Incorporated N-substituted-4-pyrimidinamines and pyrimidinediamines
US4983608A (en) * 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
JPH03127790A (en) 1989-10-11 1991-05-30 Morishita Pharmaceut Co Ltd N-(1h-tetrazol-5-yl)-2-anilino-5-pyrimidinecarboxamides and synthetic intermediate therefor
TW224941B (en) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
US5532228A (en) * 1990-02-06 1996-07-02 Schering Aktiengesellschaft Side-chain homologous vitamin D derivatives, process for their production, pharmaceutical preparations containing these derivatives and their use as pharmaceutical agents
DE4011682A1 (en) * 1990-04-06 1991-10-10 Schering Ag 24-OXA DERIVATIVES IN THE VITAMIN D SERIES
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
DE4029650A1 (en) 1990-09-19 1992-03-26 Hoechst Ag New 2-aryl:amino-pyrimidine derivs. - contg. alkynyl gp., useful as fungicides
ATE152102T1 (en) * 1991-05-10 1997-05-15 Takeda Chemical Industries Ltd PYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE
US5200400A (en) * 1991-07-12 1993-04-06 New England Deaconess Hospital Corporation Method for inhibiting allograft rejection using photoactivatable nucleotides or nucleosides
CA2074864A1 (en) 1991-07-30 1993-01-31 Carmen Almansa Tetralones with pharmacological activity
US5728536A (en) * 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
DE4141746A1 (en) * 1991-12-13 1993-06-17 Schering Ag 20-METHYL-SUBSTITUTED VITAMIN D DERIVATIVES
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5194431A (en) * 1992-07-08 1993-03-16 Wisconsin Alumni Research Foundation 24-cyclopropane vitamin D derivatives
TW287160B (en) * 1992-12-10 1996-10-01 Hoffmann La Roche
CZ101496A3 (en) 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
IL112290A (en) 1994-01-12 1999-01-26 Novartis Ag Substituted aryl and heteroaryl pyrimidines and herbicidal compositions containing them
CA2150609C (en) 1994-06-01 1998-12-08 Mikiro Yanaka Pyrimidine derivatives and pharmaceutical composition
US5733932A (en) * 1995-01-06 1998-03-31 The Picower Institute For Medical Research Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US6316635B1 (en) * 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
GB9516121D0 (en) 1995-08-05 1995-10-04 Pfizer Ltd Organometallic addition to ketones
US6069144A (en) 1995-08-24 2000-05-30 Basf Aktiengesellschaft N-heterocyclic compounds, intermediate products used to prepare them, agents containing them and their use in antifungal applications
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP4058129B2 (en) * 1996-03-18 2008-03-05 株式会社資生堂 Pyridine derivatives and anti-ulcer agents, antibacterial agents
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US6696448B2 (en) * 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
US6004985A (en) 1996-10-09 1999-12-21 Berlex Laboratories, Inc. Thio acid derived monocylic N-heterocyclics as anticoagulants
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6316429B1 (en) * 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6486185B1 (en) * 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6987113B2 (en) * 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
SE9702401D0 (en) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
GB9723859D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Compound,composition and use
DE19750701A1 (en) * 1997-11-15 1999-05-20 Dystar Textilfarben Gmbh & Co Reaction of F-substituted triazine and pyrimidine compounds with amino compounds
AU1507199A (en) * 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
KR20010033811A (en) * 1997-12-31 2001-04-25 토마스 안 빅토리아 Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
NZ506292A (en) * 1998-02-13 2003-05-30 Upjohn Co Substituted aminophenyl isoxazoline methylamide derivatives useful as antimicrobials
DE69909756D1 (en) * 1998-02-17 2003-08-28 Tularik Inc ANTIVIRAL PYRIMIDINE DERIVATIVES
DE69943247D1 (en) 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV-inhibiting pyrimidine derivatives
DK0945443T3 (en) 1998-03-27 2003-06-02 Janssen Pharmaceutica Nv HIV inhibitory pyrimidine derivatives
GB9806739D0 (en) 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
EP1054871A2 (en) * 1998-04-01 2000-11-29 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
AU768721B2 (en) * 1998-04-15 2004-01-08 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma
EP1080087A4 (en) 1998-05-22 2001-11-21 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds
EP1091739A1 (en) 1998-06-30 2001-04-18 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
WO2000010981A1 (en) 1998-08-21 2000-03-02 Parker Hughes Institute Quinazoline derivatives
DE69933680T2 (en) 1998-08-29 2007-08-23 Astrazeneca Ab PYRIMIDINE COMPOUNDS
DE19851421A1 (en) 1998-11-07 2000-05-11 Boehringer Ingelheim Pharma New pyrimidines, their production and use
KR100658489B1 (en) 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. HIV replication inhibiting pyrimidines
WO2000027802A1 (en) * 1998-11-12 2000-05-18 Ariad Pharmaceuticals, Inc. Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
US6127376A (en) 1998-12-04 2000-10-03 Berlex Laboratories, Inc. Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6624171B1 (en) * 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904995D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
SE9901079D0 (en) 1999-03-23 1999-03-23 Astra Ab Novel compounds
EE200100502A (en) 1999-03-26 2002-12-16 Astrazeneca Ab Compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
CA2369945A1 (en) 1999-04-06 2000-10-12 James L. Kelley Neurotrophic thio substituted pyrimidines
DE19917785A1 (en) 1999-04-20 2000-10-26 Bayer Ag New 2,4-diamino-pyrimidine derivatives useful as microbicides in protection of plants and materials and as herbicides
WO2000076980A1 (en) 1999-06-10 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
BR0013952A (en) 1999-09-15 2002-05-14 Warner Lambert Co Pteridinones as kinase inhibitors
KR100820605B1 (en) 1999-09-24 2008-04-08 얀센 파마슈티카 엔.브이. Antiviral compositions
DE19945982A1 (en) 1999-09-24 2001-03-29 Knoll Ag Velocity-determined particles
NZ517575A (en) 1999-09-30 2004-04-30 Neurogen Corp Certain alkylene diamine-substituted heterocycles
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
KR100317935B1 (en) 1999-10-20 2001-12-22 유승필 Pharmaceutical compositions and preparations for treatment of metabolic bone disease
WO2001030782A2 (en) 1999-10-29 2001-05-03 Syngenta Participations Ag Novel herbicides
AU4903201A (en) 1999-11-30 2001-07-03 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
CA2393640C (en) 1999-12-10 2006-09-05 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine compounds
AR029423A1 (en) * 1999-12-21 2003-06-25 Sugen Inc COMPOSITE DERIVED FROM PIRROLO- [PIRIMIDIN OR PIRIDIN] -6-ONA, METHOD OF PREPARATION OF THESE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, A METHOD FOR REGULATING, MODULATING OR INHIBITING THE ACTIVITY OF THE PROTEIN QUINASA AND ONE METHOD MAMMALS DISEASE
DE60043397D1 (en) 1999-12-28 2010-01-07 Pharmacopeia Inc CYTOKINE, PARTICULAR TNF-ALPHA, HEMMER
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
ATE369844T1 (en) 2000-01-24 2007-09-15 Genzyme Corp JAK/STAT PATHWAY INHIBITORS AND THEIR USE IN THE TREATMENT OF GENERAL PRIMARY OSTEOARTHRITIS
WO2001056993A2 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
AU782775B2 (en) * 2000-02-05 2005-08-25 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of ERK
CN1429222A (en) 2000-02-17 2003-07-09 安姆根有限公司 Kinase inhibitors
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
US6608048B2 (en) * 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
AR028261A1 (en) 2000-03-28 2003-04-30 Wyeth Corp TRICICLIC INHIBITORS OF PROTEIN QUINASA
JP5230050B2 (en) 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ HIV replication inhibitor
EP1282607B1 (en) 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Prodrugs of hiv replication inhibiting pyrimidines
CZ20023993A3 (en) 2000-06-26 2004-02-18 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine compounds functioning as immunosuppressive agents
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
DE60118576T2 (en) 2000-08-18 2006-11-02 3M Innovative Properties Co., Saint Paul FLUORO (METH) ACRYLATECOPOLYMER coating compositions
AU2001291013A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6777441B2 (en) * 2000-10-02 2004-08-17 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
AU2001229722A1 (en) 2000-11-29 2002-06-11 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20020115173A1 (en) * 2000-12-11 2002-08-22 Children's Medical Center Corporation Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity
WO2002047690A1 (en) 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
AR035721A1 (en) * 2000-12-20 2004-07-07 Sugen Inc INDOLINONES 4-ARIL SUBSTITUTED; ITS PHARMACEUTICAL COMPOSITIONS AND METHOD TO MODULATE THE CATALYTIC ACTIVITY OF A PROTEIN KINASE
JP4253188B2 (en) 2000-12-21 2009-04-08 グラクソ グループ リミテッド Pyrimidineamine as an angiogenesis regulator
AU2001297619B2 (en) 2000-12-21 2006-06-08 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2436487A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
AUPR279101A0 (en) 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
BR0207096A (en) 2001-02-20 2004-01-20 Astrazeneca Ab Use of a compound, compounds, pharmaceutical formulation, and method of treatment and / or prophylaxis of conditions associated with glycogen synthase kinase-3 inhibition
GB2373186A (en) 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
ATE324371T1 (en) 2001-02-23 2006-05-15 Merck & Co Inc N-SUBSTITUTED HETEROCYCLIC NONARYL NMDA/NR2B ANTAGONISTS
ATE497603T1 (en) * 2001-03-02 2011-02-15 Gpc Biotech Ag THREE-HYBRID ASSAY SYSTEM
ES2320204T3 (en) * 2001-05-29 2009-05-20 Bayer Schering Pharma Aktiengesellschaft CDK INHIBITING PYRIMIDINES, ITS PREPARATION AND ITS USE AS MEDICATIONS.
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
MXPA03010961A (en) * 2001-05-31 2004-02-27 Vertex Pharma Thiazole compounds useful as inhibitors of protein kinases.
CA2446756C (en) 2001-06-01 2011-03-08 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
CA2450769A1 (en) * 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
WO2002102313A2 (en) 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Pyrimidine inhibitors of phosphodiesterase (pde) 7
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP1408978A4 (en) 2001-06-21 2005-07-13 Ariad Pharma Inc Novel phenylamino-pyrimidines and uses thereof
AP2003002929A0 (en) * 2001-06-23 2003-12-31 Aventis Pharma Inc Pyrrolopyrimidines as protein kinase inhibitors
EP1406875B1 (en) 2001-06-26 2013-07-31 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
JO3429B1 (en) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidines derivatives
US7115617B2 (en) * 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7070996B2 (en) * 2001-08-31 2006-07-04 Rigel Pharmaceuticals, Inc. Production of cultured human mast cells and basophils for high throughput small molecule drug discovery
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
EP1436259A1 (en) * 2001-09-10 2004-07-14 Congxin Liang 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003026665A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
WO2003040141A1 (en) * 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
EP1453516A2 (en) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG Novel tri-substituted pyrimidines, method for production and use thereof as medicament
UY27487A1 (en) 2001-10-17 2003-05-30 Boehringer Ingelheim Pharma PIRIMIDINE DERIVATIVES, MEDICATIONS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURE FOR PREPARATION
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
IL162210A0 (en) 2001-11-28 2005-11-20 Btg Int Ltd Preventives or remedies for alzheimer's disease oramyloid protein fibrosis inhibitors containing ni trogen-containing heteroaryl
GT200200234A (en) 2001-12-06 2003-06-27 NEW CRYSTAL COMPOUNDS
SE0104140D0 (en) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
AU2002367172A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
WO2003062225A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US7459455B2 (en) 2002-02-08 2008-12-02 Smithkline Beecham Corporation Pyrimidine compounds
WO2003074515A1 (en) 2002-03-01 2003-09-12 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
WO2003076437A1 (en) 2002-03-11 2003-09-18 Schering Aktiengesellschaft Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003301758A1 (en) 2002-05-06 2004-05-25 Bayer Pharmaceuticals Corporation Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
AR039540A1 (en) 2002-05-13 2005-02-23 Tibotec Pharm Ltd MICROBICIDE COMPOUNDS WITH PIRIMIDINE OR TRIAZINE CONTENT
JP2005528443A (en) 2002-05-30 2005-09-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド Inhibitors of JAK kinase and CDK2 protein kinase
WO2003106451A1 (en) 2002-06-14 2003-12-24 Altana Pharma Ag Substituted diaminopyrimidines
US20060252943A1 (en) 2002-06-17 2006-11-09 Amogh Boloor Chemical process
CN1665789A (en) 2002-06-28 2005-09-07 山之内制药株式会社 Diaminopyrimidinecarboxa mide derivative
US6758434B2 (en) * 2002-07-03 2004-07-06 Kimberly-Clark Worldwide, Inc. Dispenser for multiple rolls of sheet material
ES2337782T3 (en) 2002-07-29 2010-04-29 Rigel Pharmaceuticals, Inc. METHODS TO TREAT OR PREVENT AUTOIMMUNITY DISEASES WITH 2,4-PYRIMIDINDIAMINE COMPOUNDS.
AU2003249539A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
JP4741948B2 (en) 2002-08-14 2011-08-10 バーテックス ファーマシューティカルズ インコーポレイテッド Protein kinase inhibitors and their use
DE10243291B4 (en) * 2002-09-18 2015-04-30 Mann + Hummel Gmbh Valve, in particular for the oil circuit of an internal combustion engine
AU2003286876A1 (en) 2002-11-01 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
ES2289349T3 (en) 2002-11-04 2008-02-01 Vertex Pharmaceuticals Incorporated DERIVATIVES OF HETEROARIL-PYRIMIDINE AS JAK INHIBITORS.
EP1560824A1 (en) 2002-11-05 2005-08-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
GB0226582D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
CL2003002353A1 (en) * 2002-11-15 2005-02-04 Vertex Pharma COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
CN101353321A (en) 2002-11-21 2009-01-28 辉瑞产品公司 3-amino-piperadine derivatives and methods of manufacture
KR20050086784A (en) 2002-11-26 2005-08-30 화이자 프로덕츠 인크. Method of treatment of transplant rejection
NZ539823A (en) 2002-11-28 2008-04-30 Schering Aktiengessellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2004054617A1 (en) 2002-12-13 2004-07-01 Kyowa Hakko Kogyo Co., Ltd. Preventives and/or remedies for central diseases
AU2003297160A1 (en) 2002-12-18 2004-07-22 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1590334B1 (en) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
EP1597237B1 (en) 2003-02-07 2016-07-27 Janssen Pharmaceutica NV Pyrimidine derivatives for the prevention of HIV infection
CL2004000303A1 (en) 2003-02-20 2005-04-08 Tibotec Pharm Ltd COMPOUNDS DERIVED FROM PYRIMIDINS AND TRIAZINES; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND ITS USE TO INHIBIT HIV REPLICATION.
ES2325440T3 (en) 2003-02-20 2009-09-04 Smithkline Beecham Corporation PIRIMIDINE COMPOUNDS.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2006522124A (en) * 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド Compositions useful as inhibitors of protein kinases
DE602004008762T2 (en) 2003-04-30 2008-06-12 The Institutes for Pharmaceutical Discovery, LLC, Branford SUBSTITUTED HETEROARYL COMPOUNDS AS INHIBITORS OF PROTEINTYROSINPHOSPHATASES
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2005007646A1 (en) 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
KR20060120393A (en) 2003-07-16 2006-11-27 얀센 파마슈티카 엔.브이. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
CN100549014C (en) 2003-07-16 2009-10-14 詹森药业有限公司 Triazolopyrimidine derivative as the Glycogen Synthase kinase 3 inhibitor
US20070161637A1 (en) 2003-07-22 2007-07-12 Neurogen Corporation Substituted pyridin-2-ylamine analogues
WO2005009957A1 (en) 2003-07-24 2005-02-03 Merck & Co., Inc. Tyrosine kinase inhibitors
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
NZ545270A (en) * 2003-07-30 2010-04-30 Rigel Pharmaceuticals Inc 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2005012262A1 (en) 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
DE602004032446D1 (en) 2003-08-07 2011-06-09 Rigel Pharmaceuticals Inc 2,4-PYRIMIDINDIAMIN COMPOUNDS AND USES AS ANTIPROLIFERATIVE AGENTS
MXPA06001762A (en) 2003-08-14 2006-05-12 Pfizer Piperazine derivatives for the treatment of hiv infections.
DK1660458T3 (en) 2003-08-15 2012-05-07 Irm Llc 2,4-Pyrimidine diamines useful in the treatment of neoplastic diseases, inflammatory disorders and disorders of the immune system.
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
JP2007505858A (en) 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 2,4-Di (phenylamino) pyrimidine useful for the treatment of proliferative disorders
WO2005027848A2 (en) 2003-09-19 2005-03-31 Barnes-Jewish Hospital Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
KR20060121878A (en) 2003-09-25 2006-11-29 얀센 파마슈티카 엔.브이. Hiv inhibiting purine derivatives
ATE380813T1 (en) 2003-10-03 2007-12-15 Pfizer IMIDAZOPYRIDINE-SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONISTIC EFFECTS FOR THE TREATMENT OF HIV AND INFLAMMATION
DE10349423A1 (en) 2003-10-16 2005-06-16 Schering Ag Sulfoximine-substituted parimidines as CDK and / or VEGF inhibitors, their preparation and use as medicaments
US20080312192A1 (en) 2003-11-28 2008-12-18 Guido Bold Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2005063722A1 (en) 2003-12-19 2005-07-14 Rigel Pharmaceuticals, Inc. Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
GB2432834A (en) 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7968557B2 (en) 2004-02-14 2011-06-28 Novartis Ag Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
CA2566531A1 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1598343A1 (en) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine derivatives as PLK inhibitors
US20060047135A1 (en) * 2004-08-30 2006-03-02 Chadwick Scott T Process for preparing chloromethyl di-tert-butylphosphate
EP1786783A1 (en) 2004-09-01 2007-05-23 Rigel Pharmaceuticals, Inc. Synthesis of 2,4-pyrimidinediamine compounds
EP1794134A1 (en) * 2004-09-29 2007-06-13 Bayer Schering Pharma Aktiengesellschaft Substituted 2-anilinopyrimidines as cell cycle kinase inhibitors or receptor tyrosine kinase inhibitors, production of said substances and use of the latter as medicaments
TW200626560A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines
JP2008518967A (en) * 2004-10-29 2008-06-05 ライジェル ファーマシューティカルズ， インコーポレイテッド Substituted pyridine having activity against Syk kinase
ES2380550T3 (en) 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Spiro-2,4-pyrimidinediamine compounds and their uses
WO2006074057A2 (en) 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
KR101278397B1 (en) * 2005-01-19 2013-06-25 리겔 파마슈티칼스, 인크. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2007027238A2 (en) 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
US20060251285A1 (en) 2005-05-05 2006-11-09 Mrs. Yen-Chen Chan [surge-proof damper]
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2651349T3 (en) 2005-06-08 2018-01-25 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibiting the JAK route
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
MX2008000574A (en) 2005-07-11 2008-03-14 Sanofi Aventis Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors.
KR101467723B1 (en) * 2005-11-01 2014-12-03 탈자진 인코포레이티드 Bi-aryl meta-pyrimidine inhibitors of kinases
US7713987B2 (en) * 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
BRPI0620324A2 (en) 2005-12-21 2011-11-08 Pfizer Prod Inc pyrimidine derivatives, pharmaceutical composition and use thereof
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
WO2007085540A1 (en) 2006-01-27 2007-08-02 Glaxo Group Limited 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
PL1984357T3 (en) * 2006-02-17 2014-03-31 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
JP2009528295A (en) * 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Compositions and methods for inhibition of the JAK pathway
CA2673125C (en) 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2380551T3 (en) * 2006-11-21 2012-05-16 Rigel Pharmaceuticals, Inc. Prodrug salts of 2,4-pyrimidinediamine compounds and their uses
US20100144732A1 (en) 2006-12-19 2010-06-10 Krueger Elaine B Pyrimidine kinase inhibitors
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2008118823A2 (en) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
AU2008275918B2 (en) * 2007-07-17 2014-01-30 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors

Also Published As

Publication number Publication date
IL173299A (en) 2015-05-31
WO2005016893A2 (en) 2005-02-24
JP2007500722A (en) 2007-01-18
RS53109B (en) 2014-06-30
HRP20130602T1 (en) 2013-07-31
ZA200601460B (en) 2008-04-30
US20070225495A1 (en) 2007-09-27
DK1656372T3 (en) 2013-07-01
AU2011200367B2 (en) 2012-07-26
US20070167439A1 (en) 2007-07-19
US20090318687A1 (en) 2009-12-24
WO2005012294A8 (en) 2005-12-29
US20120253039A1 (en) 2012-10-04
IL173299A0 (en) 2006-06-11
CY1114445T1 (en) 2016-08-31
US20200017523A1 (en) 2020-01-16
KR20060056353A (en) 2006-05-24
NO333771B1 (en) 2013-09-16
US9751893B2 (en) 2017-09-05
WO2005012294A1 (en) 2005-02-10
BRPI0413018B1 (en) 2018-12-26
AU2004265288A1 (en) 2005-02-24
CA2533377C (en) 2012-11-27
PL1656372T3 (en) 2013-08-30
NZ545270A (en) 2010-04-30
US20050234049A1 (en) 2005-10-20
WO2005016893A3 (en) 2005-06-09
CN102358738A (en) 2012-02-22
BRPI0413018A (en) 2006-10-03
RS20060073A (en) 2008-06-05
PT1656372E (en) 2013-06-27
US8178671B2 (en) 2012-05-15
AU2011200367A1 (en) 2011-02-17
US11230554B2 (en) 2022-01-25
US7560466B2 (en) 2009-07-14
US7452879B2 (en) 2008-11-18
EP1656372B1 (en) 2013-04-10
US10259826B2 (en) 2019-04-16
CN1849318A (en) 2006-10-18
ES2421139T3 (en) 2013-08-29
JP2011256198A (en) 2011-12-22
US20180072756A1 (en) 2018-03-15
JP4886511B2 (en) 2012-02-29
HK1091209A1 (en) 2007-01-12
EP1656372A2 (en) 2006-05-17
KR101201603B1 (en) 2012-11-14
CN1849318B (en) 2011-10-12
US20220073536A1 (en) 2022-03-10
US7122542B2 (en) 2006-10-17
US20080312438A1 (en) 2008-12-18
US20050209224A1 (en) 2005-09-22
US7582648B2 (en) 2009-09-01
SG145698A1 (en) 2008-09-29
BRPI0413018B8 (en) 2021-05-25
KR20120062863A (en) 2012-06-14
NO20060992L (en) 2006-02-28

Similar Documents

Publication Publication Date Title
CA2533377A1 (en) Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
JP2007500722A5 (en)
RU2500673C2 (en) Heterocyclic mek inhibitors and methods for use thereof
MX2007015863A (en) Sphingosine kinase inhibitors.
NO20090025L (en) Pyrrolotriazinkinaseinhibitorer
MA30226B1 (en) CYTOTOXIC AGENTS COMPRISING NOVEL TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE.
CA2451932A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
RU2009100159A (en) THIENOPYRAMIDINES USEFUL AS ION CHANNEL MODULATORS
NO20083207L (en) Inhibitors of IAP
NO20090321L (en) Use of substituted 2-aminotyethralines for the manufacture of a drug for the prevention, relief and / or treatment of various types of pain
RU2008105071A (en) COMPOUNDS AND COMPOSITIONS AS TRO MIMETICS
MX2008013836A (en) 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
MX2009011850A (en) "triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives".
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20070258L (en) Benzyltriazolone Compounds as Non-Nucleoside Reverse Transcriptase Inhibitors
UY30032A1 (en) CINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PROCESSES FOR THE PREPARATION AND USE OF THE SAME
HUP0402225A2 (en) Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them
NO20065061L (en) Benzoxazine for the treatment of respiratory diseases
MX2009006593A (en) Substituted acetophenones useful as pde4 inhibitors.
RU2006107438A (en) GMA-ERGIC MODULATORS
TW200716527A (en) Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives
DE602004018630D1 (en) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
RU2007101161A (en) 4-Phenylpyrimidine-2-Carbonitrile Derivatives
NO20073631L (en) Metasubstituted thiazolidinones, processes for the preparation and use thereof as drugs
NO20092035L (en) Thiazolyl compounds useful as kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request